Quantcast
Last updated on April 18, 2014 at 16:28 EDT

Latest HUMIRA Stories

2014-03-21 23:03:40

ResearchMoz.us include new market research report "PharmaPoint: Crohns Disease - China Drug Forecast and Market Analysis to 2022" to its huge collection of research reports. Browse full report - http://www.researchmoz.us/pharmapoint-crohns-disease-china-drug-forecast-and-market-analysis-to-2022-report.html. Albany, NY (PRWEB) March 21, 2014 The Crohns disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the...

2014-03-21 23:00:27

ChinaMarketResearchReports.com adds Latest Report on “Investigation Report on China Adalimumab Market, 2010-2018” to its store. Dallas, TX (PRWEB) March 22, 2014 Adalimumab is a TNF (tumor necrosis factor) inhibiting antiinflammatory drug, the first fully human monoclonal antibody drug approved by the FDA. It was discovered through collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology in 1993, then further manufactured at BASF Bioresearch Corporation and...

2014-03-20 08:29:06

NORTH CHICAGO, Ill., March 20, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a pivotal Phase 3 clinical trial that will evaluate the use of HUMIRA® (adalimumab) as a treatment for fingernail psoriasis in patients with moderate to severe chronic plaque psoriasis, an area of unmet need. Currently there are no approved treatments for fingernail psoriasis. "Since treatment options are limited, we welcome research that evaluates new options for patients suffering...

2013-11-14 12:26:27

Compared to One Year Ago, TNF-alpha Inhibitors Have Seen Growth in All Three Lines of Therapy, According to a New Report from Decision Resources BURLINGTON, Mass., Nov. 14, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that through examination of U.S. patient-level claims data, the TNF-alpha inhibitors drug class has seen growth in all three lines of therapy, particularly the second- and...

2013-10-29 23:22:36

Reportbuyer.com just published a new market research report: World Biological Drugs Market 2013-2023. London (PRWEB) October 29, 2013 Report Details Biologics - discover and assess products with highest revenue potential Do you want to find sales potentials of biological drugs? Visiongain's updated report gives you revenue predictions for biologics from 2013, helping you stay ahead. There you find financial data, R&D trends, opportunities, and discussions of prospects. In that...

2013-10-24 12:26:15

EU5 Payers Agree that the Requirement for Direct Comparative Data Is Increasing in the Highly Competitive RA Market, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 24, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that results from the ADACTA trial, which showed that Roche's RoActemra is superior to AbbVie's Humira as a monotherapy in biologics-naive...

2013-10-23 08:27:22

Compared with 2012, in Certain Ulcerative Colitis Disease Severities, Remicade Usage Has Decreased Significantly, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 23, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that although the patient share for Janssen's Simponi is low, gastroenterologists report a significant increase in use amongst their...

2013-10-09 12:26:03

Key Drivers of Market Growth Will Be the Uptake of Humira, Simponi, Vedolizumab and Tofacitinib, According to Findings from Decision Resources BURLINGTON, Mass., Oct. 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the ulcerative colitis drug market will increase from $2.1 billion in 2012 to $3.6 billion in 2022 in the United States, France, Germany, Italy, Spain, the...

2013-10-03 08:29:05

-- The post-hoc analysis applies a new measurement tool created by AbbVie to assess the efficacy of HS therapy NORTH CHICAGO, Ill., Oct. 3, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA(®) (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.(1) Efficacy results were reported using a novel Hidradenitis Suppurativa...

2013-09-24 23:19:33

Reportbuyer.com just published a new market research report: Inflammatory Bowel Diseases: World Drug Market 2013-2023. London (PRWEB) September 24, 2013 Report Details Medicines for bowel inflammation - you explore R&D and potential sales What's the future for treating inflammatory bowel diseases (IBD)? Visiongain's updated report gives you revenue predictions from 2013, helping you stay ahead. There you find financial results, R&D trends, opportunities, and potential...